ERBB2 and breast cancer: In an attempt to increase the drug ability by overcoming receptor heterogenicity, Houdaihed et al. developed a polymeric NP functionalized with Fab fragments to target HER2 and EGFR receptors for the delivery of paclitaxel (PTX) and Everolimus (EVER) in both monolayer and 3D breast cancer cells [120].